Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting to be held from November 6-10, in Orlando, Florida.

Details of the presentations are as follows:

ACAAI 2025, Orlando, Florida, November 6-10, 2025.Oral Presentations

• Title: Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated AngioedemaPresenter: Evangelia Pardali, Ph.D.Format: Oral PresentationDate, time: Saturday, November 8, 4:43 p.m. ET

• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label ExtensionPresenter: Marc A. Riedl, M.D., M.S.Format: Oral Presentation Date, time: Saturday, November 8, 4:53 p.m. ET

Poster Presentations

• Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1Presenter: Michael E. Manning, M.D. Format: Poster PresentationDate, time: Friday, November 7, 2:35 p.m. ET

• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 ResultsPresenter: John Anderson, M.D.Format: Poster PresentationDate, time: Friday, November 7, 2:35 p.m. ET

• Title: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched AnalysisPresenter: Mark D. Scarupa, M.D.Format: Poster PresentationDate, time: Friday, November 7, 4:35 p.m. ET

• Title: Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema AttacksPresenter: Joshua S. Jacobs, M.D.Format: Poster PresentationDate, time: Friday, November 7, 5:05 p.m. ET

• Title: Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results Presenter: John Anderson, M.D.Format: Poster PresentationDate, time: Friday, November 7, 5:20 p.m. ET

• Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema AttacksPresenter: Zhi-Yi Zhang, Ph.D.Format: Poster PresentationDate, time: Friday, November 7, 5:35 p.m. ET

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.

About PharvarisPharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.